Drug Trial Radar · NCT04615923
HEALEY ALS Platform Trial - Regimen D Pridopidine
Last checked: Nov 19, 2026Latest source record: Aug 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
163
Actual
Start
Dec 18, 2020
Primary completion
Jul 14, 2022
Study completion Jul 14, 2022
Sponsor
- Lead sponsor
- Merit E. Cudkowicz, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Prilenia
- First posted
- Nov 4, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in participants with ALS.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
PridopidineDrug
Administration: Oral Dose: 45mg twice daily
Matching PlaceboDrug
Administration: Oral Dose: one capsule twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Progression as Assessed by the ALSFRS-R Total ScoreTime frame: Baseline to 24 Weeks
- Mortality Event RateTime frame: Baseline to 24 Weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Healey Center for ALS at Mass General
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.